Drugs / LY2452473
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01275157 | Jan → Feb 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03297398 | Feb 2018 → Apr 2019 | benign prostatic hyperplasia | OPKO Health, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01160289 | Oct 2010 → Nov 2011 | erectile dysfunction | Eli Lilly and Company | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01401543 Comparator | Jul → Sep 2011 | erectile dysfunction | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT02499497 Comparator | Feb 2016 → Oct 2020 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-01-31 | OPKO Health, Inc. | Results OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator opko.com ↗
Also, although most of the laboratory changes were consistent with this class of drugs, increases in liver enzymes were observed in several men at these higher doses. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-01-31 | OPKO Health, Inc. | OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator opko.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2452473 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02499497 ↗ |
| Known as | OPK-88004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03297398 ↗ |
| Known as | TT-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3542265 ↗ |
| Action | Activate | “which is agonist on the muscle” NCT02499497 ↗ |
| Modality | Small molecule | “Selective Androgen Receptor Modulator” NCT03297398 ↗ |
| Route | Oral | “Administered orally, once daily for 12 weeks” NCT01160289 ↗ |
| Target | AR | “LY2452473 is a selective androgen receptor modulator” NCT02499497 ↗ |